A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant clostridium difficile infection in mice

Zhiyong Yang, Diane Schmidt, Weilong Liu, Shan Li, Lianfa Shi, Jinliang Sheng, Kevin Chen, Hua Yu, Jacqueline M. Tremblay, Xinhua Chen, Kurt H. Piepenbrink, Eric J. Sundberg, Ciaran P. Kelly, Guang Bai, Charles B. Shoemaker, Hanping Feng

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The incidence of Clostridium difficile infection (CDI) and associated mortality have increased rapidly worldwide in recent years. Therefore, it is critical to develop new therapies for CDI. In this study, we generated a novel, potently neutralizing, tetravalent, and bispecific antibody composed of 2 heavy-chain-only VH (VHH) binding domains against both TcdA and TcdB (designated "ABA") that reverses fulminant CDI in mice infected with an epidemic 027 strain after a single injection of the antibody. We demonstrated that ABA bound to both toxins simultaneously and displayed a significantly enhanced neutralizing activity both in vitro and in vivo. Additionally, ABA was able to broadly neutralize toxins from clinical C. difficile isolates that express both TcdA and TcdB but failed to neutralize the toxin from TcdA-TcdB+ C. difficile strains. This study thus provides a rationale for the development of multivalent VHHs that target both toxins and are broadly neutralizing for treating severe CDI.

Original languageEnglish (US)
Pages (from-to)964-972
Number of pages9
JournalJournal of Infectious Diseases
Volume210
Issue number6
DOIs
StatePublished - Jan 1 2014

Fingerprint

Single-Domain Antibodies
Clostridium Infections
Clostridium difficile
Bispecific Antibodies
Neutralizing Antibodies
Injections
Mortality
Antibodies
Incidence

Keywords

  • Antibody
  • Clostridium difficile
  • Immunotherapy
  • Toxins
  • VHH

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant clostridium difficile infection in mice. / Yang, Zhiyong; Schmidt, Diane; Liu, Weilong; Li, Shan; Shi, Lianfa; Sheng, Jinliang; Chen, Kevin; Yu, Hua; Tremblay, Jacqueline M.; Chen, Xinhua; Piepenbrink, Kurt H.; Sundberg, Eric J.; Kelly, Ciaran P.; Bai, Guang; Shoemaker, Charles B.; Feng, Hanping.

In: Journal of Infectious Diseases, Vol. 210, No. 6, 01.01.2014, p. 964-972.

Research output: Contribution to journalArticle

Yang, Z, Schmidt, D, Liu, W, Li, S, Shi, L, Sheng, J, Chen, K, Yu, H, Tremblay, JM, Chen, X, Piepenbrink, KH, Sundberg, EJ, Kelly, CP, Bai, G, Shoemaker, CB & Feng, H 2014, 'A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant clostridium difficile infection in mice', Journal of Infectious Diseases, vol. 210, no. 6, pp. 964-972. https://doi.org/10.1093/infdis/jiu196
Yang, Zhiyong ; Schmidt, Diane ; Liu, Weilong ; Li, Shan ; Shi, Lianfa ; Sheng, Jinliang ; Chen, Kevin ; Yu, Hua ; Tremblay, Jacqueline M. ; Chen, Xinhua ; Piepenbrink, Kurt H. ; Sundberg, Eric J. ; Kelly, Ciaran P. ; Bai, Guang ; Shoemaker, Charles B. ; Feng, Hanping. / A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant clostridium difficile infection in mice. In: Journal of Infectious Diseases. 2014 ; Vol. 210, No. 6. pp. 964-972.
@article{4419087c01864859ae03963d0f49ef54,
title = "A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant clostridium difficile infection in mice",
abstract = "The incidence of Clostridium difficile infection (CDI) and associated mortality have increased rapidly worldwide in recent years. Therefore, it is critical to develop new therapies for CDI. In this study, we generated a novel, potently neutralizing, tetravalent, and bispecific antibody composed of 2 heavy-chain-only VH (VHH) binding domains against both TcdA and TcdB (designated {"}ABA{"}) that reverses fulminant CDI in mice infected with an epidemic 027 strain after a single injection of the antibody. We demonstrated that ABA bound to both toxins simultaneously and displayed a significantly enhanced neutralizing activity both in vitro and in vivo. Additionally, ABA was able to broadly neutralize toxins from clinical C. difficile isolates that express both TcdA and TcdB but failed to neutralize the toxin from TcdA-TcdB+ C. difficile strains. This study thus provides a rationale for the development of multivalent VHHs that target both toxins and are broadly neutralizing for treating severe CDI.",
keywords = "Antibody, Clostridium difficile, Immunotherapy, Toxins, VHH",
author = "Zhiyong Yang and Diane Schmidt and Weilong Liu and Shan Li and Lianfa Shi and Jinliang Sheng and Kevin Chen and Hua Yu and Tremblay, {Jacqueline M.} and Xinhua Chen and Piepenbrink, {Kurt H.} and Sundberg, {Eric J.} and Kelly, {Ciaran P.} and Guang Bai and Shoemaker, {Charles B.} and Hanping Feng",
year = "2014",
month = "1",
day = "1",
doi = "10.1093/infdis/jiu196",
language = "English (US)",
volume = "210",
pages = "964--972",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant clostridium difficile infection in mice

AU - Yang, Zhiyong

AU - Schmidt, Diane

AU - Liu, Weilong

AU - Li, Shan

AU - Shi, Lianfa

AU - Sheng, Jinliang

AU - Chen, Kevin

AU - Yu, Hua

AU - Tremblay, Jacqueline M.

AU - Chen, Xinhua

AU - Piepenbrink, Kurt H.

AU - Sundberg, Eric J.

AU - Kelly, Ciaran P.

AU - Bai, Guang

AU - Shoemaker, Charles B.

AU - Feng, Hanping

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The incidence of Clostridium difficile infection (CDI) and associated mortality have increased rapidly worldwide in recent years. Therefore, it is critical to develop new therapies for CDI. In this study, we generated a novel, potently neutralizing, tetravalent, and bispecific antibody composed of 2 heavy-chain-only VH (VHH) binding domains against both TcdA and TcdB (designated "ABA") that reverses fulminant CDI in mice infected with an epidemic 027 strain after a single injection of the antibody. We demonstrated that ABA bound to both toxins simultaneously and displayed a significantly enhanced neutralizing activity both in vitro and in vivo. Additionally, ABA was able to broadly neutralize toxins from clinical C. difficile isolates that express both TcdA and TcdB but failed to neutralize the toxin from TcdA-TcdB+ C. difficile strains. This study thus provides a rationale for the development of multivalent VHHs that target both toxins and are broadly neutralizing for treating severe CDI.

AB - The incidence of Clostridium difficile infection (CDI) and associated mortality have increased rapidly worldwide in recent years. Therefore, it is critical to develop new therapies for CDI. In this study, we generated a novel, potently neutralizing, tetravalent, and bispecific antibody composed of 2 heavy-chain-only VH (VHH) binding domains against both TcdA and TcdB (designated "ABA") that reverses fulminant CDI in mice infected with an epidemic 027 strain after a single injection of the antibody. We demonstrated that ABA bound to both toxins simultaneously and displayed a significantly enhanced neutralizing activity both in vitro and in vivo. Additionally, ABA was able to broadly neutralize toxins from clinical C. difficile isolates that express both TcdA and TcdB but failed to neutralize the toxin from TcdA-TcdB+ C. difficile strains. This study thus provides a rationale for the development of multivalent VHHs that target both toxins and are broadly neutralizing for treating severe CDI.

KW - Antibody

KW - Clostridium difficile

KW - Immunotherapy

KW - Toxins

KW - VHH

UR - http://www.scopus.com/inward/record.url?scp=84907102875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907102875&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiu196

DO - 10.1093/infdis/jiu196

M3 - Article

C2 - 24683195

AN - SCOPUS:84907102875

VL - 210

SP - 964

EP - 972

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 6

ER -